Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 60,307
  • Shares Outstanding, K 42,470
  • Annual Sales, $ 70 K
  • Annual Income, $ -43,890 K
  • 36-Month Beta 1.69
  • Price/Sales 867.62
  • Price/Cash Flow 0.00
  • Price/Book 0.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.36 +5.15%
on 07/13/17
1.71 -16.37%
on 06/23/17
-0.18 (-11.18%)
since 06/21/17
3-Month
1.36 +5.15%
on 07/13/17
2.98 -52.01%
on 05/15/17
-0.77 (-35.00%)
since 04/21/17
52-Week
1.36 +5.15%
on 07/13/17
3.49 -59.03%
on 10/05/16
-1.79 (-55.59%)
since 07/21/16

Most Recent Stories

More News
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

ENZ : 11.35 (-1.05%)
ECYT : 1.43 (+0.70%)
EXEL : 27.23 (+0.89%)
SNY : 47.71 (-0.73%)
Walgreens (WBA) to Report Q3 Earnings: What's in Store?

Walgreens Boots Alliance, Inc. (WBA) is slated to release third-quarter fiscal 2017 results before the market opens on Jun 29.

HUM : 235.92 (+0.04%)
WBA : 78.90 (-1.13%)
ECYT : 1.43 (+0.70%)
ALGN : 158.87 (-0.81%)
Daily Technical Summary Reports on Biotech Stocks -- Concordia, Cytokinetics, Dermira, and Endocyte

If you want a Stock Review on CXRX, CYTK, DERM or ECYT then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com reviews the Biotechnology...

CYTK : 14.50 (+4.69%)
DERM : 29.40 (+2.80%)
CXRX : 1.52 (-0.65%)
ECYT : 1.43 (+0.70%)
Why Is Endocyte (ECYT) Down 37.9% Since the Last Earnings Report?

Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ECYT : 1.43 (+0.70%)
Blog Coverage: Endocyte to Present Posters on its Lead Clinical Stage Assets at the ASCO Annual Meeting

Upcoming AWS Coverage on Jazz Pharma Post-Earnings Results

JAZZ : 161.13 (+0.80%)
ECYT : 1.43 (+0.70%)
Today's Research Reports on Stocks to Watch: Endocyte and CytRx

NEW YORK, NY / ACCESSWIRE / May 31, 2017 / While still not anywhere the highs of 2015's boom, the Biotech Industry has shown some signs of a comeback in 2017. After a dismal 2016, the iShares NASDAQ Biotechnology...

ECYT : 1.43 (+0.70%)
CYTR : 0.60 (-4.00%)
XBI : 80.77 (+0.79%)
Endocyte to Announce Updated Data on EC1456 and EC1169 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented...

ECYT : 1.43 (+0.70%)
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

AZN : 34.05 (+0.47%)
LLY : 84.66 (-0.11%)
ECYT : 1.43 (+0.70%)
PFE : 33.48 (-0.18%)
Endocyte (ECYT) Reports Narrower-than-Expected Loss in Q1

Endocyte, Inc. (ECYT) reported a narrower-than-expected loss in the first quarter of 2017.

GALE : 0.58 (unch)
BTX : 2.97 (+1.02%)
ECYT : 1.43 (+0.70%)
INFI : 1.40 (-0.71%)
Endocyte (ECYT) Reports Narrower than Expected Q1 Loss

Endocyte reported a loss per share of 27 cents per share while our consensus called for a loss of 28 cents per share.

ECYT : 1.43 (+0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Support & Resistance

2nd Resistance Point 1.46
1st Resistance Point 1.44
Last Price 1.43
1st Support Level 1.41
2nd Support Level 1.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.